Iovance Biotherapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2020 | $-205.1M | $-251.9M | $46.8M | $40.9M |
| FY2021 | $-227.9M | $-265.5M | $37.6M | $69.8M |
| FY2022 | $-292.8M | $-313.2M | $20.4M | $84.0M |
| FY2023 | $-361.8M | $-384.1M | $22.3M | $62.6M |
| FY2024 | $-353.0M | $-364.0M | $11.1M | $109.6M |